Quéromès, G.; Frobert, E.; Bouscambert‐Duchamp, M.; Oblette, A.; Valette, M.; Billaud, G.; Escuret, V.; Lina, B.; Morfin, F.; Gaymard, A. Rapid and Reliable Inactivation Protocols for the Diagnostics of Emerging Viruses: The Example of SARS‐CoV‐2 and Monkeypox Virus. Journal of Medical Virology, 2022, 95. https://doi.org/10.1002/jmv.28126.
Quéromès, G.; Frobert, E.; Bouscambert‐Duchamp, M.; Oblette, A.; Valette, M.; Billaud, G.; Escuret, V.; Lina, B.; Morfin, F.; Gaymard, A. Rapid and Reliable Inactivation Protocols for the Diagnostics of Emerging Viruses: The Example of SARS‐CoV‐2 and Monkeypox Virus. Journal of Medical Virology, 2022, 95. https://doi.org/10.1002/jmv.28126.
Quéromès, G.; Frobert, E.; Bouscambert‐Duchamp, M.; Oblette, A.; Valette, M.; Billaud, G.; Escuret, V.; Lina, B.; Morfin, F.; Gaymard, A. Rapid and Reliable Inactivation Protocols for the Diagnostics of Emerging Viruses: The Example of SARS‐CoV‐2 and Monkeypox Virus. Journal of Medical Virology, 2022, 95. https://doi.org/10.1002/jmv.28126.
Quéromès, G.; Frobert, E.; Bouscambert‐Duchamp, M.; Oblette, A.; Valette, M.; Billaud, G.; Escuret, V.; Lina, B.; Morfin, F.; Gaymard, A. Rapid and Reliable Inactivation Protocols for the Diagnostics of Emerging Viruses: The Example of SARS‐CoV‐2 and Monkeypox Virus. Journal of Medical Virology, 2022, 95. https://doi.org/10.1002/jmv.28126.
Abstract
Following the rapid spread of COVID-19 across the globe, the intense response that was demanded of diagnostic centers and research laboratories prompted the use of numerous products and protocols for the management of SARS-CoV-2 specimens. In these settings, proper handling of such infectious specimen is necessary to ensure the safety of personnel and to reduce the risk of active transmission. Our aim was to evaluate the inactivation efficacy of different inactivating methods, notably from commercial lysis buffers available in diagnostic kits. Heat and sodium dodecyl sulfate detergent were also included in our investigations. A cell culture-based assay was used, and supported by molecular qRT-PCR detection, to show in vitro infectivity reduction after inactivation treatment. Overall, all the investigated methods were successful in inactivating SARS-CoV-2. Ten minutes of contact with the commercial buffers completely stopped in vitro SARS-CoV-2 infectivity. Fifteen minutes at 68°C and 30 minutes at 56°C as well as one hour with sodium dodecyl sulfate detergent at 2, 1, 0.5, and 0.1% yielded the same results. These findings demonstrate the reliability of these protocols with regards to biosafety. Inactivation by heat and sodium dodecyl sulfate detergent are rather simple and can be readily available methods for rendering an infectious SARS-CoV-2 specimen inactive, especially in settings where commercial buffers are not available.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
*
